MYELODYSPLASTIC SYNDROME(MDS)
Clinical trials for MYELODYSPLASTIC SYNDROME(MDS) explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROME(MDS) trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROME(MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental drug tested for Post-Transplant blood cancers — but study halted early
Disease control TerminatedThis pilot study tested the drug ADCT-301 in 3 adults whose acute myeloid leukemia, myelodysplastic syndrome, or related blood cancer had returned after a stem cell transplant. The goal was to see if the drug could safely bring about remission. However, the study was terminated e…
Matched conditions: MYELODYSPLASTIC SYNDROME(MDS)
Phase: PHASE2 • Sponsor: Gwynn Long, M.D. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental MDS combo trial halted early – what we know
Disease control TerminatedThis phase 2 study tested adding sabatolimab, an experimental immunotherapy, to standard chemotherapy drugs (azacitidine, decitabine, or oral decitabine) in 39 adults with intermediate to very high risk myelodysplastic syndrome (MDS). The main goal was to check safety, and the tr…
Matched conditions: MYELODYSPLASTIC SYNDROME(MDS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New immunotherapy combo shows promise for Tough-to-Treat MDS
Disease control TerminatedThis phase 2 trial tested a new drug called sabatolimab, combined with two standard chemotherapy drugs (azacitidine and venetoclax), in 20 adults with high or very high risk myelodysplastic syndromes (MDS) who could not have intensive chemotherapy or a stem cell transplant. The g…
Matched conditions: MYELODYSPLASTIC SYNDROME(MDS)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC